<DOC>
	<DOCNO>NCT01129024</DOCNO>
	<brief_summary>This Phase 2 , multicenter , open-label , dose-ranging , parallel-group extension study evaluate safety S-888711 treatment subject immune thrombocytopenia . Patients participate study must complete Phase 2 double-blind , randomize control study .</brief_summary>
	<brief_title>An Open-label Safety Study S-888711</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>A sign date write informed consent Males females â‰¥ 18 year age All subject must agree use barrier contraception Diagnosis ITP Subjects &gt; 60 year must diagnostic bone marrow aspiration Relapsed persistent chronic ITP status Subjects receive steroid therapy must stable dose PT APTT within 20 % upper limit normal Subjects receive stable dosage cyclosporine A , mycophenolate mofetil , azathioprine , danazol allow History clinically important hemorrhagic clot disorder Females pregnant , lactating , take oral contraceptive History alcohol/drug abuse dependence within 1 year Use follow drug treatment prior Visit 1 ( Day 1 ) : Within 1 week Rho ( D ) immune globulin intravenous immunoglobulin ; Within 2 week plasmaphoresis treatment ; Within 4 week use antiplatelet anticoagulant drug ; Within 8 week rituximab ; Within 12 week alemtuzumab , multidrug systemic chemotherapy , stem cell therapy ; History clinically significant cardiovascular thromboembolic disease within 26 week prior Initial Screening Splenectomy within 4 week prior Initial Screening Clinically significant laboratory abnormality Hemoglobin &lt; 10.0 g/dL men woman , clearly relate ITP Absolute neutrophil count &lt; 1000/mm3 Abnormal peripheral blood smear evidence fibrosis confirm bonemarrow biopsy Total bilirubin &gt; 1.5 x upper limit normal Alanine aminotransferase ( ALT ) &gt; 1.5 x upper limit normal Aspartate aminotransferase ( AST ) &gt; 1.5 x upper limit normal Creatinine &gt; 1.5 x upper limit normal Human immunodeficiency virus positive Hepatitis A IgM antibody positive , hepatitis B surface antigen hepatitis C antibody positive Exposure previous TPO mimetics/agonists ( e.g. , eltrombopag , romiplostim , E5501 [ AKR501 ] LGD4665 ) within 4 week prior Initial Screening Subjects unresponsive previous TPO mimetics/agonists ( e.g. , eltrombopag , romiplostim , E5501 [ AKR501 ] LGD4665 ) Exposure investigative medication within 4 week prior initial Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Splenectomy</keyword>
	<keyword>Low Platelet Count</keyword>
	<keyword>Thrombopoiesis</keyword>
	<keyword>Thrombocytopaenia</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Immune Thrombocytopenia ( ITP )</keyword>
	<keyword>Thrombotic Thrombocytopenic Purpura ( ITP )</keyword>
	<keyword>Hematologic Disease</keyword>
	<keyword>Auto-immune Thrombocytopenic Purpura</keyword>
	<keyword>S-888711</keyword>
	<keyword>Blood Platelet Disorders</keyword>
	<keyword>Relapsed Persistent Chronic ITP</keyword>
	<keyword>ITP</keyword>
</DOC>